A randomized, prospective, active-controlled study comparing intramuscular long-acting paliperidone palmitate versus oral antipsychotics in patients with schizophrenia at risk of violent behavior

被引:1
|
作者
Wang, Gang [1 ]
Huang, Huiteng [1 ]
Wang, Yijun [1 ]
Yang, Yongde [1 ]
Li, Chang [1 ]
Luo, Sen [1 ]
Li, Yi [1 ,2 ]
机构
[1] Wuhan Mental Hlth Ctr, Wuhan, Peoples R China
[2] Wuhan Mental Hlth Ctr, 89 Gongnongbing Rd, Wuhan, Hubei, Peoples R China
关键词
Schizophrenia; Violence; Aggression; Paliperidone palmitate; Community-based; INJECTABLE ANTIPSYCHOTICS; MEDICATION ADHERENCE; FAMILY CAREGIVERS; SOCIAL COGNITION; BURDEN; PREVALENCE; CHINA;
D O I
10.1016/j.pnpbp.2023.110897
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Paliperidone palmitate (PP) is an effective long-acting antipsychotic injection, but its impact on the behavior of schizophrenia patients with dangerous tendencies requires further investigation. This study aims to explore the effects of long-term antipsychotic treatment on this population in the community.Methods: This 49-week, randomized controlled trial was conducted across 21 communities in Wuhan and enrolled 134 schizophrenia patients at risk for violent behavior. With a fixed block size of 10, participants were randomly assigned to receive either intramuscular PP 1-month formulation (PP1M) or oral antipsychotic medication (OAP) at a 1:1 ratio. Changes in patients' risk for violent/aggressive behavior, family burden, social, and cognitive functioning were measured using VRAPP, MOAS, PANSS, FBS, PSP, and RBANS scales from baseline to endpoint. Longitudinal data from multiple repeated measures were analyzed using linear mixed-effects models.Results: The study protocol was completed by 77.6% of the patients overall. Significant improvements were observed in the risk assessment scores, MOAS total score, PANSS total score, PSP total score, and FBS total score of patients in the PP1M group from baseline to the end of treatment (all P < 0.05). Importantly, compared to patients in the OAP group, the improvements in these measures were also significantly greater in the PP1M group. Commonly observed AEs, such as hyperprolactinemia (70.3% vs. 62.65%) and muscle tension (45.3% vs. 57.8%), were considered to be the PP-related AEs. Nonetheless, the differences between the two groups did not reach statistical significance, and no new safety concerns emerged.Conclusions: Our study suggests that PP long-acting injection (LAI) is a safe and effective treatment option for community-dwelling schizophrenia patients with impulsive violence and risky behaviors.
引用
收藏
页数:9
相关论文
共 50 条
  • [21] Paliperidone Palmitate versus Risperidone Long-Acting Injectable in Patients with Schizophrenia: A Meta-Analysis of Efficacy and Safety
    Zhao, Mingjun
    Qin, Bin
    Mao, Yage
    Zhang, Yang
    Zhao, Ruisheng
    Wang, Aiqin
    Wang, Hailing
    Zhao, Jianting
    Wang, Changhong
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 749 - 757
  • [22] Cortical thickness, gray-white matter contrast, and intracortical myelin in first-episode schizophrenia patients treated with long-acting paliperidone palmitate versus oral antipsychotics
    Wang, C.
    Tishler, T. A.
    Nuechterlein, K. H.
    Ellingson, B. M.
    PSYCHIATRY RESEARCH, 2023, 326
  • [23] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Cai, Qian
    Patel, Charmi
    Kim, Edward
    Connolly, Nancy
    Tunceli, Ozgur
    El Khoury, Antoine C.
    ADVANCES IN THERAPY, 2019, 36 (04) : 858 - 869
  • [24] Factors Associated with the Initiation of Long-Acting Injectable Paliperidone Palmitate Versus Aripiprazole Among Medicaid Patients with Schizophrenia: An Observational Study
    Qian Cai
    Charmi Patel
    Edward Kim
    Nancy Connolly
    Ozgur Tunceli
    Antoine C. El Khoury
    Advances in Therapy, 2019, 36 : 858 - 869
  • [25] A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia
    Schreiner, A.
    Korcsog, P.
    Niehaus, D. J.
    Aadamsoo, K.
    Ucok, A.
    Franco, M.
    Theodoropoulou, P.
    Salinas, R.
    Bergmans, P.
    Hoeben, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 239 - 239
  • [26] A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF PALIPERIDONE ER VERSUS ORAL OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA
    Schreiner, A.
    Korcsog, P.
    Niehaus, D. J. H.
    Aadamsoo, K.
    Uecok, A.
    Franco, M.
    Theodoropoulou, P.
    Salinas, R.
    Bergmans, P.
    Hoeben, D.
    Tessier, C.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [27] Population Pharmacokinetics of Intramuscular Paliperidone Palmitate in Patients with Schizophrenia A Novel Once-Monthly, Long-Acting Formulation of an Atypical Antipsychotic
    Samtani, Mahesh N.
    Vermeulen, An
    Stuyckens, Kim
    CLINICAL PHARMACOKINETICS, 2009, 48 (09) : 585 - 600
  • [28] A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF PALIPERIDONE ER VERSUS ORAL OLANZAPINE IN PATIENTS WITH SCHIZOPHRENIA
    Schreiner, Andreas
    Korcsog, Peter
    Niehaus, D. J. H.
    Aadamsoo, Kaire
    Ucok, Alp
    Franco, Manuel
    Theodoropoulou, P.
    Salinas, R.
    Bergmans, Paul
    Hoeben, Dagmar
    Tessier, Christophe
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 384 - 384
  • [29] A prospective randomized controlled trial of paliperidone ER versus oral olanzapine in patients with schizophrenia
    Tessier, C.
    Hoeben, D.
    Korcsog, P.
    Niehaus, D. J. H.
    Aadamsoo, K.
    Ucok, A.
    Franco, M.
    Theodoropoulou, P.
    Salinas, R.
    Schreiner, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S479 - S479
  • [30] COST-UTILITY ANALYSIS OF PALIPERIDONE PALMITATE LONG ACTING INJECTION(PLAI) VERSUS ORAL ATYPICAL ANTIPSYCHOTICS IN NON-ADHERENT SCHIZOPHRENIA PATIENTS
    Kim, B. R. M.
    Lee, T. J.
    Woo, J. M.
    Park, J., I
    Kwon, J. S.
    VALUE IN HEALTH, 2011, 14 (07) : A294 - A294